COSTEM 2019 | Can CAR-T cells replace ASCT in DLBCL?

Arnon Nagler

Arnon Nagler, MD, MSc, Tel Aviv University, Tel Aviv, Israel, discusees the efficacy of CAR-T cells in diffuse large B-cell lymphoma (DLBCL) compared to that of autologous stem cell transplantation (ASCT). This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

Share this video  
Similar topics